Raffaele De Francesco

List of Publications by Year
in descending order

135	12,109	17440 63	26613 107
papers	citations	h-index	g-index

141	141	141	12621
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Crystal structure of a eukaryotic zinc-dependent histone deacetylase, human HDAC8, complexed with a hydroxamic acid inhibitor. Proceedings of the National Academy of Sciences of the United States of America, 2004, 101, 15064-15069.	7.1	573
2	Transcriptional Landscape of Human Tissue Lymphocytes Unveils Uniqueness of Tumor-Infiltrating T Regulatory Cells. Immunity, 2016, 45, 1135-1147.	14.3	510
3	Challenges and successes in developing new therapies for hepatitis C. Nature, 2005, 436, 953-960.	27.8	404
4	Structural Analysis of the Hepatitis C Virus RNA Polymerase in Complex with Ribonucleotides. Journal of Virology, 2002, 76, 3482-3492.	3.4	338
5	Inhibition of Hepatitis C Virus RNA Replication by 2â€²-Modified Nucleoside Analogs. Journal of Biological Chemistry, 2003, 278, 11979-11984.	3.4	314
6	The crystal structure of the quorum sensing protein TraR bound to its autoinducer and target DNA. EMBO Journal, 2002, 21, 4393-4401.	7.8	306
7	Characterization of Resistance to Non-obligate Chain-terminating Ribonucleoside Analogs That Inhibit Hepatitis C Virus Replication in Vitro. Journal of Biological Chemistry, 2003, 278, 49164-49170.	3.4	305
8	Human CD1c+ dendritic cells secrete high levels of IL-12 and potently prime cytotoxic T-cell responses. Blood, 2013, 122, 932-942.	1.4	300
9	The long intergenic noncoding RNA landscape of human lymphocytes highlights the regulation of T cell differentiation by linc-MAF-4. Nature Immunology, 2015, 16, 318-325.	14.5	300
10	Structural and Functional Analysis of the Human HDAC4 Catalytic Domain Reveals a Regulatory Structural Zinc-binding Domain. Journal of Biological Chemistry, 2008, 283, 26694-26704.	3.4	259
11	Complex of NS3 protease and NS4A peptide of BK strain hepatitis C virus: A 2.2 Ã… resolution structure in a hexagonal crystal form. Protein Science, 1998, 7, 837-847.	7.6	235
12	Substrate binding to histone deacetylases as shown by the crystal structure of the HDAC8â€“substrate complex. EMBO Reports, 2007, 8, 879-884.	4.5	230
13	Product Inhibition of the Hepatitis C Virus NS3 Protease. Biochemistry, 1998, 37, 8899-8905.	2.5	229
14	Distinct microRNA signatures in human lymphocyte subsets and enforcement of the naive state in CD4+ T cells by the microRNA miR-125b. Nature Immunology, 2011, 12, 796-803.	14.5	222
15	Mechanismof Action and Antiviral Activity of Benzimidazole-Based AllostericInhibitors of the Hepatitis C Virus RNA-Dependent RNAPolymerase. Journal of Virology, 2003, 77, 13225-13231.	3.4	198
16	Approaching a new era for hepatitis C virus therapy: inhibitors of the NS3-4A serine protease and the NS5B RNA-dependent RNA polymerase. Antiviral Research, 2003, 58, 1-16.	4.1	187
17	A myosin-like dimerization helix and an extra-large homeodomain are essential elements of the tripartite DNA binding structure of LFB1. Cell, 1990, 61, 1225-1236.	28.9	181
18	Multiple Enzymatic Activities Associated with Recombinant NS3 Protein of Hepatitis C Virus. Journal of Virology, 1998, 72, 6758-6769.	3.4	178

#	Article	IF	Citations
19	Potent Peptide Inhibitors of Human Hepatitis C Virus NS3 Protease Are Obtained by Optimizing the Cleavage Products. Biochemistry, 1998, 37, 8906-8914.	2.5	174
20	A designed P1 cysteine mimetic for covalent and non-covalent inhibitors of HCV NS3 protease. Bioorganic and Medicinal Chemistry Letters, 2002, 12, 701-704.	2.2	167
21	Effects of pH and Low Density Lipoprotein (LDL) on PCSK9-dependent LDL Receptor Regulation. Journal of Biological Chemistry, 2007, 282, 20502-20512.	3.4	166
22	IL28B polymorphisms predict interferon-related hepatitis B surface antigen seroclearance in genotype D hepatitis B e antigen-negative patients with chronic hepatitis B. Hepatology, 2013, 57, 890-896.	7.3	153
23	Interdomain Communication in Hepatitis C Virus Polymerase Abolished by Small Molecule Inhibitors Bound to a Novel Allosteric Site. Journal of Biological Chemistry, 2005, 280, 29765-29770.	3.4	152
24	Inhibition of class I histone deacetylase with an apicidin derivative prevents cardiac hypertrophy and failure. Cardiovascular Research, 2008, 80, 416-424.	3.8	147
25	Phosphorylation of hepatitis C virus NS5A nonstructural protein: A new paradigm for phosphorylation-dependent viral RNA replication?. Virology, 2007, 364, 1-9.	2.4	144
26	New horizons in hepatitis C antiviral therapy with direct-acting antivirals. Hepatology, 2013, 58, 428-438.	7.3	142
27	Discovery of Î±,Î³-Diketo Acids as Potent Selective and Reversible Inhibitors of Hepatitis C Virus NS5b RNA-Dependent RNA Polymerase. Journal of Medicinal Chemistry, 2004, 47, 14-17.	6.4	139
28	Oxysterol-Binding Protein Is a Phosphatidylinositol 4-Kinase Effector Required for HCV Replication Membrane Integrity and Cholesterol Trafficking. Gastroenterology, 2014, 146, 1373-1385.e11.	1.3	138
29	Reduction of Hepatitis C Virus NS5A Hyperphosphorylation by Selective Inhibition of Cellular Kinases Activates Viral RNA Replication in Cell Culture. Journal of Virology, 2004, 78, 13306-13314.	3.4	128
30	Characterization of the Inhibition of Hepatitis C Virus RNA Replication by Nonnucleosides. Journal of Virology, 2004, 78, 938-946.	3.4	128
31	Advances in the development of new therapeutic agents targeting the NS3-4A serine protease or the NS5B RNA-dependent RNA polymerase of the hepatitis C virus. Advanced Drug Delivery Reviews, 2007, 59, 1242-1262.	13.7	128
32	A Continuous Assay of Hepatitis C Virus Protease Based on Resonance Energy Transfer Depsipeptide Substrates. Analytical Biochemistry, 1996, 240, 60-67.	2.4	125
33	In Vitro Selection and Characterization of Hepatitis C Virus Serine Protease Variants Resistant to an Active-Site Peptide Inhibitor. Journal of Virology, 2003, 77, 3669-3679.	3.4	120
34	Inhibition of the Hepatitis C Virus NS3/4A Protease. Journal of Biological Chemistry, 2000, 275, 7152-7157.	3.4	116
35	Genetic variation in the interleukin -28B gene is not associated with fibrosis progression in patients with chronic hepatitis C and known date of infection. Hepatology, 2011, 54, 1127-1134.	7.3	115
36	Structural and Biochemical Characterization of the Wild Type PCSK9-EGF(AB) Complex and Natural Familial Hypercholesterolemia Mutants. Journal of Biological Chemistry, 2009, 284, 1313-1323.	3.4	112

#	Article	IF	Citations
37	Hyperphosphorylation of the Hepatitis C Virus NS5A Protein Requires an Active NS3 Protease, NS4A, NS4B, and NS5A Encoded on the Same Polyprotein. Journal of Virology, 1999, 73, 9984-9991.	3.4	112
38	The solution structure of the N-terminal proteinase domain of the hepatitis C virus (HCV) NS3 protein provides new insights into its activation and catalytic mechanism. Journal of Molecular Biology, 1999, 289, 371-384.	4.2	111
39	Substrate Specificity of the Hepatitis C Virus Serine Protease NS3. Journal of Biological Chemistry, 1997, 272, 9204-9209.	3.4	109
40	Metabolism of Phosphatidylinositol 4-Kinase IIIÎ±-Dependent PI4P Is Subverted by HCV and Is Targeted by a 4-Anilino Quinazoline with Antiviral Activity. PLoS Pathogens, 2012, 8, e1002576.	4.7	108
41	Integrated longitudinal immunophenotypic, transcriptional, and repertoire analyses delineate immune responses in patients with COVID-19. Science Immunology, 2021, 6, .	11.9	108
42	Molecular virology of the hepatitis C virus. Journal of Hepatology, 1999, 31, 47-53.	3.7	106
43	Kinetic Analyses Reveal Potent and Early Blockade of Hepatitis C Virus Assembly by NS5A Inhibitors. Gastroenterology, 2014, 147, 453-462.e7.	1.3	104
44	A Zinc Binding Site in Viral Serine Proteinases. Biochemistry, 1996, 35, 13282-13287.	2.5	103
45	HCV NS5b RNA-Dependent RNA Polymerase Inhibitors:â€‰ From Î±,Î³-Diketoacids to 4,5-Dihydroxypyrimidine- or 3-Methyl-5- hydroxypyrimidinonecarboxylic Acids. Design and Synthesis. Journal of Medicinal Chemistry, 2004, 47, 5336-5339.	6.4	103
46	Potent Inhibitors of Subgenomic Hepatitis C Virus RNA Replication through Optimization of Indole-N-Acetamide Allosteric Inhibitors of the Viral NS5B Polymerase. Journal of Medicinal Chemistry, 2005, 48, 4547-4557.	6.4	102
47	Development and Preliminary Optimization of Indole-N-Acetamide Inhibitors of Hepatitis C Virus NS5B Polymerase. Journal of Medicinal Chemistry, 2005, 48, 1314-1317.	6.4	93
48	Selection of RNA Aptamers That Are Specific and High-Affinity Ligands of the Hepatitis C Virus RNA-Dependent RNA Polymerase. Journal of Virology, 2002, 76, 3688-3696.	3.4	91
49	Probing the elusive catalytic activity of vertebrate class IIa histone deacetylases. Bioorganic and Medicinal Chemistry Letters, 2008, 18, 1814-1819.	2.2	91
50	2-(2-Thienyl)-5,6-dihydroxy-4-carboxypyrimidines as Inhibitors of the Hepatitis C Virus NS5B Polymerase:Â Discovery, SAR, Modeling, and Mutagenesis. Journal of Medicinal Chemistry, 2006, 49, 1693-1705.	6.4	90
51	Rare Pathogenic Variants Predispose to Hepatocellular Carcinoma in Nonalcoholic Fatty Liver Disease. Scientific Reports, 2019, 9, 3682.	3.3	85
52	In Vitro Activity of Hepatitis C Virus Protease NS3 Purified from Recombinant Baculovirus-infected Sf9 Cells. Journal of Biological Chemistry, 1996, 271, 6367-6373.	3.4	81
53	Interleukin 28B polymorphism predicts pegylated interferon plus ribavirin treatment outcome in chronic hepatitis C genotype 4. Hepatology, 2012, 55, 336-342.	7.3	81
54	Î±-Ketoacids Are Potent Slow Binding Inhibitors of the Hepatitis C Virus NS3 Protease. Biochemistry, 2000, 39, 1849-1861.	2.5	77

#	Article	IF	Citations
55	Hepatitis C Virus NS5A Is a Direct Substrate of Casein Kinase I-Î±, a Cellular Kinase Identified by Inhibitor Affinity Chromatography Using Specific NS5A Hyperphosphorylation Inhibitors. Journal of Biological Chemistry, 2007, 282, 5536-5544.	3.4	76
56	Circular dichroism study on the conformational stability of the dimerization domain of transcription factor LFB1. Biochemistry, 1991, 30, 143-147.	2.5	75
57	The Î± Isoform of Protein Kinase CKI Is Responsible for Hepatitis C Virus NS5A Hyperphosphorylation. Journal of Virology, 2006, 80, 11305-11312.	3.4	71
58	Biochemical characterization of a hepatitis C virus RNA-dependent RNA polymerase mutant lacking the C-terminal hydrophobic sequence. Journal of General Virology, 2000, 81, 759-767.	2.9	71
59	[4] RNA-dependent RNA polymerase of hepatitis C virus. Methods in Enzymology, 1996, 275, 58-67.	1.0	68
60	A novel, inducible, eukaryotic gene expression system based on the quorumâ€sensing transcription factor TraR. EMBO Reports, 2003, 4, 159-165.	4.5	68
61	A series of novel, potent, and selective histone deacetylase inhibitors. Bioorganic and Medicinal Chemistry Letters, 2006, 16, 5948-5952.	2.2	68
62	Complex Formation between the Hepatitis C Virus Serine Protease and A Synthetic NS4A Cofactor Peptide. Biochemistry, 1997, 36, 7890-7897.	2.5	65
63	Modulation of Hepatitis C Virus NS3 Protease and Helicase Activities through the Interaction with NS4A. Biochemistry, 1999, 38, 5620-5632.	2.5	64
64	Ezrin is a specific and direct target of protein tyrosine phosphatase PRL-3. Biochimica Et Biophysica Acta - Molecular Cell Research, 2008, 1783, 334-344.	4.1	64
65	In vitro antibiofilm activity of bioactive glass S53P4. Future Microbiology, 2014, 9, 593-601.	2.0	64
66	Structural characterization of the interactions of optimized product inhibitors with the N-terminal proteinase domain of the hepatitis C virus (HCV) NS3 protein by NMR and modelling studies. Journal of Molecular Biology, 1999, 289, 385-396.	4.2	63
67	Discovery of (7R)-14-Cyclohexyl-7-{[2-(dimethylamino)ethyl](methyl) amino}-7,8-dihydro-6H-indolo[1,2-e][1,5]benzoxazocine-11-carboxylic Acid (MK-3281), a Potent and Orally Bioavailable Finger-Loop Inhibitor of the Hepatitis C Virus NS5B Polymerase. Journal of Medicinal Chemistry, 2011, 54, 289-301.	6.4	63
68	Administration of aerosolized SARS-CoV-2 to K18-hACE2 mice uncouples respiratory infection from fatal neuroinvasion. Science Immunology, 2022, 7, .	11.9	61
69	The Metal Binding Site of the Hepatitis C Virus NS3 Protease. Journal of Biological Chemistry, 1998, 273, 18760-18769.	3.4	60
70	Photodynamic antibacterial and antibiofilm activity of RLP068/Cl against Staphylococcus aureus and Pseudomonas aeruginosa forming biofilms on prosthetic material. International Journal of Antimicrobial Agents, 2014, 44, 47-55.	2.5	60
71	Genome-Wide Analysis of DNA Methylation, Copy Number Variation, and Gene Expression in Monozygotic Twins Discordant for Primary Biliary Cirrhosis. Frontiers in Immunology, 2014, 5, 128.	4.8	57
72	The monoethyl ester of meconic acid is an active site inhibitor of HCV NS5B RNA-dependent RNA polymerase. Bioorganic and Medicinal Chemistry Letters, 2004, 14, 3257-3261.	2.2	56

#	Article	IF	Citations
73	A Novel Series of Potent and Selective Ketone Histone Deacetylase Inhibitors with Antitumor Activity in Vivo. Journal of Medicinal Chemistry, 2008, 51, 2350-2353.	6.4	56
74	The Enigmatic Role of Viruses in Multiple Sclerosis: Molecular Mimicry or Disturbed Immune Surveillance?. Trends in Immunology, 2017, 38, 498-512.	6.8	56
75	Review HCV Antiviral Resistance: The Impact of in vitro Studies on the Development of Antiviral Agents Targeting the Viral NS5B Polymerase. Antiviral Chemistry and Chemotherapy, 2005, 16, 225-245.	0.6	55
76	COVID-eVax, an electroporated DNA vaccine candidate encoding the SARS-CoV-2 RBD, elicits protective responses in animal models. Molecular Therapy, 2022, 30, 311-326.	8.2	54
77	Transmembrane 6 superfamily member 2 gene E167K variant impacts on steatosis and liver damage in chronic hepatitis C patients. Hepatology, 2015, 62, 111-117.	7.3	52
78	Tuning a cellular lipid kinase activity adapts hepatitis C virus to replication in cell culture. Nature Microbiology, 2017, 2, 16247.	13.3	52
79	ILâ€10 promotes homeostatic proliferation of human CD8⁺ memory TÂcells and, when produced by CD1c⁺ DCs, shapes naive CD8⁺ Tâ€cell priming. European Journal of Immunology, 2016, 46, 1622-1632.	2.9	45
80	Identification and Biological Evaluation of a Series of 1H-Benzo[de]isoquinoline-1,3(2H)-diones as Hepatitis C Virus NS5B Polymerase Inhibitors. Journal of Medicinal Chemistry, 2009, 52, 5217-5227.	6.4	42
81	Anti-spike antibodies and neutralising antibody activity in people living with HIV vaccinated with COVID-19 mRNA-1273 vaccine: a prospective single-centre cohort study. Lancet Regional Health - Europe, The, 2022, 13, 100287.	5.6	39
82	Synthetic Depsipeptide Substrates for the Assay of Human Hepatitis C Virus Protease. Analytical Biochemistry, 1996, 237, 239-244.	2.4	38
83	Identification of New Autoantigens by Protein Array Indicates a Role for IL4 Neutralization in Autoimmune Hepatitis. Molecular and Cellular Proteomics, 2012, 11, 1885-1897.	3.8	38
84	New therapies on the horizon for hepatitis C. Clinics in Liver Disease, 2003, 7, 211-242.	2.1	37
85	Phenethyl Amides as Novel Noncovalent Inhibitors of Hepatitis C Virus NS3/4A Protease:â€‰ Discovery, Initial SAR, and Molecular Modeling. Journal of Medicinal Chemistry, 2003, 46, 345-348.	6.4	37
86	Naturally Occurring Hepatitis C Virus Subgenomic Deletion Mutants Replicate Efficiently in Huh-7 Cells and Are trans -Packaged In Vitro To Generate Infectious Defective Particles. Journal of Virology, 2009, 83, 9079-9093.	3.4	36
87	Loss of Histone Deacetylase 4 Causes Segregation Defects during Mitosis of p53-Deficient Human Tumor Cells. Cancer Research, 2009, 69, 6074-6082.	0.9	36
88	Synthesis and SAR of piperazinyl-N-phenylbenzamides as inhibitors of hepatitis C virus RNA replication in cell culture. Bioorganic and Medicinal Chemistry Letters, 2009, 19, 1779-1783.	2.2	35
89	Enzymatic properties of hepatitis C virus NS3-associated helicase. Microbiology (United Kingdom), 2000, 81, 1335-1345.	1.8	32
90	Multiple Determinants Influence Complex Formation of the Hepatitis C Virus NS3 Protease Domain with Its NS4A Cofactor Peptide. Biochemistry, 1999, 38, 5206-5215.	2.5	31

#	Article	IF	Citations
91	DEPDC5 variants increase fibrosis progression in Europeans with chronic hepatitis C virus infection. Hepatology, 2016, 63, 418-427.	7.3	31
92	The Hepatitis C Virus NS3 Proteinase: Structure and Function of a Zinc-Containing Serine Proteinase. Antiviral Therapy, 1998, 3, 99-109.	1.0	30
93	Design of Selective Eglin Inhibitors of HCV NS3 Proteinase. Biochemistry, 1998, 37, 11459-11468.	2.5	29
94	Biochemical and Immunologic Properties of the Nonstructural Proteins of the Hepatitis C Virus: Implications for Development of Antiviral Agents and Vaccines. Seminars in Liver Disease, 2000, Volume 20, 0069-0084.	3.6	28
95	Hepatitis C Virus-Specific Directly Acting Antiviral Drugs. Current Topics in Microbiology and Immunology, 2013, 369, 289-320.	1.1	27
96	Structural insights of a highly potent pan-neutralizing SARS-CoV-2 human monoclonal antibody. Proceedings of the National Academy of Sciences of the United States of America, 2022, 119, e2120976119.	7.1	27
97	Proton resonance assignment and secondary structure determination of the dimerization domain of transcription factor LFB1. Biochemistry, 1991, 30, 148-153.	2.5	26
98	Redesigning the substrate specificity of the hepatitis C virus NS3 protease. Folding & Design, 1996, 1, 35-42.	4.5	26
99	Mechanism of Hepatitis C Virus RNA Polymerase Inhibition with Dihydroxypyrimidines. Antimicrobial Agents and Chemotherapy, 2010, 54, 977-983.	3.2	26
100	Conformational changes in the NS3 protease from hepatitis C virus strain Bk monitored by limited proteolysis and mass spectrometry. Protein Science, 1999, 8, 1445-1454.	7.6	23
101	Mutational analysis of hepatitis C virus NS3-associated helicase. Microbiology (United Kingdom), 2000, 81, 1649-1658.	1.8	20
102	Anatomy of Omicron BA.1 and BA.2 neutralizing antibodies in COVID-19 mRNA vaccinees. Nature Communications, 2022, 13, .	12.8	20
103	Flavodoxin-cytochrome c interactions: circular dichroism and nuclear magnetic resonance studies. Biochemistry, 1987, 26, 5042-5048.	2.5	19
104	A Structure-Guided Approach to an Orthogonal Estrogen-Receptor-Based Gene Switch Activated by Ligands Suitable for in Vivo Studies. Journal of Medicinal Chemistry, 2006, 49, 5404-5407.	6.4	19
105	The Association of Il28b Genotype with the Histological Features of Chronic Hepatitis C Is HCV Genotype Dependent. International Journal of Molecular Sciences, 2014, 15, 7213-7224.	4.1	19
106	Probing the Active Site of the Hepatitis C Virus Serine Protease by Fluorescence Resonance Energy Transfer. Journal of Biological Chemistry, 2000, 275, 15106-15113.	3.4	18
107	A Functionally Orthogonal Estrogen Receptor-Based Transcription Switch Specifically Induced by a Nonsteroid Synthetic Ligand. Chemistry and Biology, 2005, 12, 883-893.	6.0	18
108	Mutations in Encephalomyocarditis Virus 3A Protein Uncouple the Dependency of Genome Replication on Host Factors Phosphatidylinositol 4-Kinase IIIÎ± and Oxysterol-Binding Protein. MSphere, 2016, 1, .	2.9	18

#	Article	IF	Citations
109	DNA aptamers masking angiotensin converting enzyme 2 as an innovative way to treat SARS-CoV-2 pandemic. Pharmacological Research, 2022, 175, 105982.	7.1	18
110	A High-Throughput Radiometric Assay for Hepatitis C Virus NS3 Protease. Analytical Biochemistry, 1999, 266, 192-197.	2.4	17
111	Structural Basis for Resistance of the Genotype 2b Hepatitis C Virus NS5B Polymerase to Site A Non-Nucleoside Inhibitors. Journal of Molecular Biology, 2009, 390, 1048-1059.	4.2	16
112	The dimerization domain of LFB1/HNF1 related transcription factors: a hidden four helix bundle?. Protein Engineering, Design and Selection, 1992, 5, 749-757.	2.1	14
113	Rational design and functional expression of a constitutively active single-chain NS4Aâ€“NS3 proteinase. Folding & Design, 1998, 3, 433-441.	4.5	14
114	Hepatitis C Virus Deletion Mutants Are Found in Individuals Chronically Infected with Genotype 1 Hepatitis C Virus in Association with Age, High Viral Load and Liver Inflammatory Activity. PLoS ONE, 2015, 10, e0138546.	2.5	14
115	LFB1/HNF1 acts as a repressor of its own transcription. Nucleic Acids Research, 1994, 22, 4284-4290.	14.5	12
116	NS5A inhibitors unmask differences in functional replicase complex half-life between different hepatitis C virus strains. PLoS Pathogens, 2017, 13, e1006343.	4.7	12
117	Binding of a Noncovalent Inhibitor Exploiting the Sâ€² region Stabilizes the Hepatitis C virus NS3 Protease Conformation in the Absence of Cofactor. Journal of Molecular Biology, 2009, 385, 1142-1155.	4.2	11
118	Influence of 8.alpha.-imidazole substitution of the FMN cofactor on the rate of electron transfer from the neutral semiquinones of two flavodoxins to cytochrome c. Biochemistry, 1987, 26, 5036-5042.	2.5	10
119	Interaction between PNPLA3 I148M Variant and Age at Infection in Determining Fibrosis Progression in Chronic Hepatitis C. PLoS ONE, 2014, 9, e106022.	2.5	9
120	Kinetic Studies on the Electron-Transfer Reaction between Cytochrome c3 and Flavodoxin from Desulfovibrio vulgaris Strain Hildenborough. Biochemistry, 1994, 33, 10386-10392.	2.5	8
121	Nanoparticleâ€Mediated Suicide Gene Therapy for Triple Negative Breast Cancer Treatment. Advanced Therapeutics, 2020, 3, 2000007.	3.2	7
122	Interleukin 28B Genotype and Insulin Resistance in Chronic Hepatitis C Patients. Antiviral Therapy, 2014, 19, 747-753.	1.0	6
123	pKa values of the 8Î±-imidazole substituents in selected flavoenzymes containing 8Î±-histidylflavins. Archives of Biochemistry and Biophysics, 1988, 264, 281-287.	3.0	5
124	Development and optimization of a binding assay for histone deacetylase 4 using surface plasmon resonance. Analytical Biochemistry, 2008, 377, 267-269.	2.4	5
125	Daclatasvir: a team player rather than a prima donna in the treatment of hepatitis C. Gut, 2015, 64, 860-862.	12.1	5
126	Proteases of the Hepatitis C Virus. , 1999, , 61-91.		5

#	Article	IF	Citations
127	Crystallization and preliminary X-ray diffraction studies of the transcriptional regulator TraR bound to its cofactor and to a specific DNA sequence. Acta Crystallographica Section D: Biological Crystallography, 2002, 58, 1362-1364.	2.5	4
128	A scintillation proximity active site binding assay for the hepatitis C virus serine protease. Analytical Biochemistry, 2002, 307, 99-104.	2.4	4
129	Cirrhosis and Rapid Virological Response to Peginterferon Plus Ribavirin Determine Treatment Outcome in HCV-1 IL28B rs12979860 CC Patients. BioMed Research International, 2013, 2013, 1-6.	1.9	3
130	Novel interferon-sensitive genes unveiled by correlation-driven gene selection and systems biology. Scientific Reports, 2021, 11, 18043.	3.3	3
131	Administration of aerosolized SARS-CoV-2 to K18-hACE2 mice uncouples respiratory infection from fatal neuroinvasion. Science Immunology, 2021, , eabl9929.	11.9	3
132	The 37 kDa/67 kDa laminin receptor is required for PrPSc propagation in scrapieâ€infected neuronal cells. EMBO Reports, 2003, 4, 439-439.	4.5	2
133	Measurement of homonuclear three-bond J(H(N)Halpha) coupling constants in unlabeled peptides complexed with labeled proteins: application to a decapeptide inhibitor bound to the proteinase domain of the NS3 protein of hepatitis C virus (HCV). Journal of Biomolecular NMR, 2001, 20, 23-29.	2.8	1
134	Hepatitis C vaccines. , 2013, , 1074-1084.		0
135	Immunosuppressant Treatment in Rheumatic Musculoskeletal Diseases Does Not Inhibit Elicitation of Humoral Response to SARS-CoV-2 Infection and Preserves Effector Immune Cell Populations. Frontiers in Immunology, 0, 13, .	4.8	0